by Gurumantra | Jul 5, 2015 | Health
While hemp is a commonly misunderstood ingredient—no thanks to its cousin marijuana—it offers a wide variety of both health and sustainability benefits.
Though future controversies may arise related to THC content and confusion over CBD, this increasingly popular ingredient has industry experts deeming hemp the industry’s next big star.
This slide show was adapted from a presentation by Tom Vierhile, innovative insights director, Datamonitor Consumer, at Ingredient Marketplace 2015. The full presentation is also available to download.
informative . You’ll be up to speed on the distinctions between hemp and marijuana and the bright future for both.
by Gurumantra | Jul 4, 2015 | Complimentary Alternative, Conditions, Therapy
25 June 2015 Mary Ann Liebert, Inc., Publishers
“…carefully prescribed medical use of marijuana may in fact be appropriate and we should follow the science as opposed to ideology on this issue,”
Mary Ann Liebert, publisher of the newly launched peer-reviewed open access journal Cannabis and Cannabinoid Research, strongly supports President Obama’s statement that “…carefully prescribed medical use of marijuana may in fact be appropriate and we should follow the science as opposed to ideology on this issue,” when asked about a pending Senate bill seeking to change federal law regarding state-legalized medical marijuana programs.
Cannabis and Cannabinoid Research, a fully open access journal will be the authoritative source for research, discussion, and debate. Mary Ann Liebert, Inc., publishers (http://www.liebertpub.com/) will publish the Journal under the Creative Commons Attribution 4.0 (CC BY) license to ensure broad dissemination and participation.
Cannabis and Cannabinoid Research will publish fully peer-reviewed, evidence-based original articles, review articles, and perspectives on cannabis, cannabinoids, and the endocannabinoid system.
The Journal will publish a broad range of human and animal studies including basic and translational research; clinical studies; behavioral, social, and epidemiological issues; and ethical, legal, and regulatory controversies.
An interdisciplinary community including pharmacologists and psychopharmacologists, toxicologists, biochemists, neurologists, psychiatrists, physicians, and other healthcare practitioners, addiction specialists, and regulators and policymakers are invited to participate in this new open access resource.
Topics in Cannabis and Cannabinoid Research will include: Biochemical process of the endocannabinoid system * Cannabinoid receptors and signaling
* Pharmaceuticals based on cannabis and cannabinoids * Optimal dosing and drug delivery
* Short- and long-term effects on the brain and behavior * Toxicological studies
* Analgesic effects, including neuropathic pain and chronic nerve injury
* Neurological disorders, including epilepsy, multiple sclerosis, and glaucoma * Use of cannabis as antinauseants and antispasmodics
* Immune function and chronic inflammation, including HIV * Cancer and cancer-related treatment
* Screening and assessment for marijuana misuse and addiction * Social, behavioral, and public health impact
* Ethics, regulation, legalization, and public policy.
Cannabis and Cannabinoid Research (http://www.liebertpub.com/can) will build a central forum and repository for peer-reviewed open access papers, as more high-quality research is needed to move the field forward.
“Cannabis research and its applications for therapy will create new challenges as its promise is evaluated,” says Mary Ann Liebert, founder, President, and CEO of the company that bears her name.
“Scientists in the lab and those on the front lines of patient care now have an important new educational forum. Cannabis and Cannabinoid Research (http://www.liebertpub.com/can, which is fully open access, will be the Journal of record.”
